Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences

References

• Woodworth TG, Den Broeder AA. Treating to target in established rheumatoid arthritis: challenges and opportunities in an era of novel targeted therapies and biosimilars. Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4–5):543–549.
   PubMed Web of Science ®Google Scholar
• Chaabo K, Kirkham B. Rheumatoid arthritis - anti-TNF. Int Immunopharmacol. 2015 Aug;27(2):180–184.
   PubMed Web of Science ®Google Scholar
• Weaver AL. Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol. 2003 Apr;9(2):99–114.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002 Sep;46(9):2287–2293.
   PubMed Web of Science ®Google Scholar
• Carmona L, Descalzo MA, Ruiz-Montesinos D, et al. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford). 2011 Jan;50(1):85–92.
   PubMed Web of Science ®Google Scholar
• Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011 May;70(5):785–791.
   PubMed Web of Science ®Google Scholar
• Busquets N, Tomero E, Descalzo MA, et al. Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. Rheumatology (Oxford). 2011 Nov;50(11):1999–2004.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yang S, Patkar NM, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Jul;66(7):990–997.
   PubMed Web of Science ®Google Scholar
• Beutler B, Grau GE. Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med. 1993 Oct;21(10 Suppl):S423–35.
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007 Oct;66(10):1339–1344.
   PubMed Web of Science ®Google Scholar
• Cobo-Ibanez T, Descalzo MA, Loza-Santamaria E, et al. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. Rheumatol Int. 2014 Jul;34(7):953–961.
   PubMed Web of Science ®Google Scholar
• Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015 Jul 18;386(9990):258–265.
   PubMed Web of Science ®Google Scholar
• Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005 Nov;52(11):3403–3412.
   PubMed Web of Science ®Google Scholar
• Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials. Am J Med. 2014 Dec;127(12):1208–1232.
   PubMed Web of Science ®Google Scholar
• Hernandez MV, Sanmarti R, Canete JD. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Expert Opin Drug Saf. 2016 May;15(5):613–624.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014 Mar;73(3):529–535.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2006 Aug;54(8):2368–2376.
   PubMed Web of Science ®Google Scholar
• Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis. 2005 Aug 1; 41(Suppl 3):S199–203.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 Oct 11;345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, et al., BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003 Aug;48(8):2122–2127.
   PubMed Web of Science ®Google Scholar
• Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999 Dec 4;354(9194):1932–1939.
   PubMed Web of Science ®Google Scholar
• Solovic I, Sester M, Gomez-Reino JJ, et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J. 2010 Nov;36(5):1185–1206.
   PubMed Web of Science ®Google Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009 Jul;60(7):1884–1894.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010 Mar;69(3):522–528.
   PubMed Web of Science ®Google Scholar
• Souto A, Maneiro JR, Salgado E, et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014 Oct;53(10):1872–1885.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004 May 1;38(9):1261–1265.
   PubMed Web of Science ®Google Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006 Sep 15;43(6):717–722.
   PubMed Web of Science ®Google Scholar
• Fonseca JE, Canhao H, Silva C, et al. Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience. Acta Reumatol Port. 2006 Jul-Sep;31(3):247–253.
   PubMedGoogle Scholar
• Scallon BJ, Trinh H, Nedelman M, et al. Functional comparisons of different tumour necrosis factor receptor/IgG fusion proteins. Cytokine. 1995 Nov;7(8):759–770.
   PubMed Web of Science ®Google Scholar
• Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. J Immunol. 2002 Apr 1;168(7):3394–3401.
   PubMed Web of Science ®Google Scholar
• Van Den Brande J, Hommes DW, Peppelenbosch MP. Infliximab induced T lymphocyte apoptosis in Crohn’s disease. J Rheumatol Suppl. 2005 Mar;74:26–30.
   PubMedGoogle Scholar
• Pena-Sagredo JL, Hernandez MV, Fernandez-Llanio N, et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience. Clin Exp Rheumatol. 2008 Sep-Oct;26(5):854–859.
   PubMed Web of Science ®Google Scholar
• Bowie VL, Snella KA, Gopalachar AS, et al. Listeria meningitis associated with infliximab. Ann Pharmacother. 2004 Jan;38(1):58–61.
   PubMed Web of Science ®Google Scholar
• Kesteman T, Yombi JC, Gigi J, et al. Listeria infections associated with infliximab: case reports. Clin Rheumatol. 2007 Dec;26(12):2173–2175.
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum. 2003 Feb;48(2):319–324.
   PubMed Web of Science ®Google Scholar
• Doraiswamy VA. Nocardia infection with adalimumab in rheumatoid arthritis. J Rheumatol. 2008 Mar;35(3):542–543.
   PubMed Web of Science ®Google Scholar
• Wendling D, Murad M, Mathieu S, et al. Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers. J Rheumatol. 2008 Mar;35(3):539–542.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009 Feb 18;301(7):737–744.
   PubMed Web of Science ®Google Scholar
• Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol. 2015 May 8;7(7):954–967.
   PubMedGoogle Scholar
• Tavakolpour S, Alavian SM, Sali S. Hepatitis B reactivation during immunosuppressive therapy or cancer chemotherapy, management, and prevention: a comprehensive review-screened. Hepat Mon. 2016 Mar 26;16(4):e35810.
   PubMed Web of Science ®Google Scholar
• Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016 Jan;68(1):1–26.
   PubMed Web of Science ®Google Scholar
• Ballanti E, Conigliaro P, Chimenti MS, et al. Use of anti-tumor necrosis factor alpha therapy in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective analysis of 32 patients. Drug Dev Res. 2014 Nov;75(Suppl 1):S42–5.
   PubMed Web of Science ®Google Scholar
• Chen YM, Chen HH, Chen YH, et al. A comparison of safety profiles of tumour necrosis factor alpha inhibitors and rituximab therapy in patients with rheumatoid arthritis and chronic hepatitis C. Ann Rheum Dis. 2015 Mar;74(3):626–627.
   PubMed Web of Science ®Google Scholar
• Lin KM, Cheng TT, Lin JC, et al. Tumor necrosis factor-alpha antagonist therapy for concomitant rheumatoid arthritis and hepatitis C virus infection: a case series study. Clin Rheumatol. 2015 Jun;34(6):1039–1046.
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Samonis G, Boumpas DT, et al. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc. 2008 Feb;83(2):181–194.
   PubMed Web of Science ®Google Scholar
• Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002 Oct;46(10):2565–2570.
   PubMed Web of Science ®Google Scholar
• Foster CS, Forstot SL, Wilson LA. Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Effects of systemic immunosuppression. Ophthalmology. 1984 Oct;91(10):1253–1263.
   PubMed Web of Science ®Google Scholar
• McGavin DD, Williamson J, Forrester JV, et al. Episcleritis and scleritis. A study of their clinical manifestations and association with rheumatoid arthritis. Br J Ophthalmol. 1976 Mar;60(3):192–226.
   PubMed Web of Science ®Google Scholar
• Ahn JK, Yu HG, Chung H, et al. Intraocular cytokine environment in active Behcet uveitis. Am J Ophthalmol. 2006 Sep;142(3):429–434.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001 Sep-Oct;33(5):251–255.
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systematic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21(1):19–27.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar;121(3):785,96.e3.
   Web of Science ®Google Scholar
• Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006 May;113(5):860,4.e2.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Lowder CY, Goldstein DA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013 Apr;97(4):481–486.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol. 2007 May;34(5):1146–1150.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016 Sep 8;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016 Sep 17;388(10050):1183–1192.
   PubMed Web of Science ®Google Scholar
• Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001 Jun;44(6):1411–1415.
   PubMed Web of Science ®Google Scholar
• Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003 Apr;121(4):437–440.
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? Observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010 Aug;35(8):751–756.
   PubMed Web of Science ®Google Scholar
• Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009 Jan;104(1):228–233.
   PubMed Web of Science ®Google Scholar
• Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003 Jul 28;21(24):3365–3369.
   PubMed Web of Science ®Google Scholar
• Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.
   PubMed Web of Science ®Google Scholar
• Ngian GS, Briggs AM, Ackerman IN, et al. Management of pregnancy in women with rheumatoid arthritis. Med J Aust. 2016 Feb 1;204(2):62–63.
   PubMed Web of Science ®Google Scholar
• Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis. 2009 Nov;68(11):1793–1794.
   PubMed Web of Science ®Google Scholar
• Keeling S, Wolbink GJ. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis. J Rheumatol. 2010 Jul;37(7):1551.
   PubMed Web of Science ®Google Scholar
• Fechtenbaum M, Md Yusof MY, Emery P. Certolizumab pegol in rheumatoid arthritis: current update. Expert Opin Biol Ther. 2014 Jun;14(6):841–850.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar;11(3):286,92;quiz e24.
   PubMed Web of Science ®Google Scholar
• Ngian GS, Briggs AM, Ackerman IN, et al. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis. 2016 Sep;19(9):834–843.
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med. 2013 Jul 31;11:174,7015-11-174.
   PubMed Web of Science ®Google Scholar
• Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-alpha inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015 Oct;80(4):727–739.
   PubMed Web of Science ®Google Scholar
• Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014 Jan;43:78–84.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011 Feb;106(2):214,23; quiz 224.
   PubMed Web of Science ®Google Scholar
• Clowse ME, Wolf DC, Forger F, et al. Pregnancy outcomes in subjects exposed to certolizumab pegol. J Rheumatol. 2015 Dec;42(12):2270–2278.
   PubMed Web of Science ®Google Scholar
• Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer. 1996 Sep;32A(10):1753–1757.
   PubMed Web of Science ®Google Scholar
• Smitten AL, Simon TA, Hochberg MC, et al. A meta-analysis of the incidence of malignancy in adult patients with trials. Ann Rheum Dis. 2009 Jul;68(7):1177–1183.
   PubMed Web of Science ®Google Scholar
• Hellgren K, Baecklund E, Backlin C, et al. Rheumatoid arthritis and risk of malignant lymphoma - is the risk still increased?. Arthritis Rheumatol. 2017 Apr;69(4):700–708.
   PubMed Web of Science ®Google Scholar
• Raaschou P, Simard JF, Asker Hagelberg C, et al., ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden. BMJ. 2016 Jan; 28(352):i262.
   Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006 May 17;295(19):2275–2285.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009 Jul;68(7):1177–1183.
   PubMed Web of Science ®Google Scholar
• Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012 Sep 5;308(9):898–908.
   PubMed Web of Science ®Google Scholar
• Carmona L, Abasolo L, Descalzo MA, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum. 2011 Aug;41(1):71–80.
   PubMed Web of Science ®Google Scholar
• Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Ann Rheum Dis. 2015 Jun;74(6):1087–1093.
   PubMed Web of Science ®Google Scholar
• Silva-Fernandez L, Lunt M, Kearsley-Fleet L, et al. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-rheumatoid arthritis. Rheumatology (Oxford). 2016 Nov;55(11):2033–2039.
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12(1):R5.
   PubMed Web of Science ®Google Scholar
• Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 2007 Sep;56(9):2905–2912.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Furer V, Farkouh ME. Cardiovascular safety of biologic therapies for the treatment of RA. Nat Rev Rheumatol. 2011 Nov 15; 8(1):13–21.
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011 Apr;70(4):576–582.
   PubMed Web of Science ®Google Scholar
• Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003 Jul 1;107(25):3133–3140.
   PubMed Web of Science ®Google Scholar
• Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004 Apr 6;109(13):1594–1602.
   PubMed Web of Science ®Google Scholar
• Keiserman M, Codreanu C, Handa R, et al. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences. Expert Rev Clin Immunol. 2014 Aug;10(8):1049–1057.
   PubMed Web of Science ®Google Scholar
• Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013 Mar;9(3):164–172.
   PubMed Web of Science ®Google Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011 Apr 13;305(14):1460–1468.
   PubMed Web of Science ®Google Scholar
• Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Mar;54(3):711–715.
   PubMed Web of Science ®Google Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015 Aug;29(4):241–258.
   PubMed Web of Science ®Google Scholar
• Mok CC, Tsai WC, Chen DY, et al. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016 Feb;16(2):201–211.
   PubMed Web of Science ®Google Scholar
• Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis. 2013 Dec;72(12):1947–1955.
   PubMed Web of Science ®Google Scholar
• Drug labels for TNF inhibitors [Internet]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/.
   Google Scholar
• Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2012 Feb;12(2):235–249.
   PubMed Web of Science ®Google Scholar
• Pasut G. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol. BioDrugs. 2014 Apr;28(Suppl 1):S15–23.
   PubMed Web of Science ®Google Scholar
• Batycka-Baran A, Flaig M, Molin S, et al. Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. Expert Opin Drug Saf. 2012 Nov;11(6):911–921.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004 Jul;50(7):2264–2272.
   PubMed Web of Science ®Google Scholar
• Dogra S, Khullar G. Tumor necrosis factor-alpha antagonists: side effects and their management. Indian J Dermatol Venereol Leprol. 2013 Jul;79(Suppl 7):S35–46.
   PubMed Web of Science ®Google Scholar
• Kerbleski JF, Gottlieb AB. Dermatological complications and safety of anti-TNF treatments. Gut. 2009 Aug;58(8):1033–1039.
   PubMed Web of Science ®Google Scholar
• Meroni PL, Valesini G. Tumour necrosis factor alpha antagonists in the treatment of rheumatoid arthritis: an immunological perspective. BioDrugs. 2014 Apr;28(Suppl 1):S5–13.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002 May 4;359(9317):1541–1549.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr 15;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Choquette D, Faraawi R, Chow A, et al. Incidence and management of infusion reactions to infliximab in a prospective real-world community registry. J Rheumatol. 2015 Jul;42(7):1105–1111.
   PubMed Web of Science ®Google Scholar
• Kelsall J, Rogers P, Galindo G, et al. Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions. J Rheumatol. 2012 Aug;39(8):1539–1545.
   PubMed Web of Science ®Google Scholar
• De Vries HS, Van Oijen MG, Driessen RJ, et al. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br J Clin Pharmacol. 2011 Jan;71(1):7–19.
   PubMed Web of Science ®Google Scholar
• Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003 Jun;98(6):1315–1324.
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001 Dec;44(12):2862–2869.
   PubMed Web of Science ®Google Scholar
• Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey. Rheumatology (Oxford). 2013 May;52(5):868–874.
   PubMed Web of Science ®Google Scholar
• Fernandez-Espartero MC, Perez-Zafrilla B, Naranjo A, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum. 2011 Feb;40(4):330–337.
   PubMed Web of Science ®Google Scholar
• De Mattos BR, Garcia MP, Nogueira JB, et al. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments. Mediators Inflamm. 2015;2015:493012.
   PubMed Web of Science ®Google Scholar
• Zenlea T, Peppercorn MA. Immunosuppressive therapies for inflammatory bowel disease. World J Gastroenterol. 2014 Mar 28;20(12):3146–3152.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001 Nov;121(5):1088–1094.
   PubMed Web of Science ®Google Scholar
• Barthel D, Ganser G, Kuester RM, et al. Inflammatory bowel disease in juvenile idiopathic arthritis patients treated with biologics. J Rheumatol. 2015 Nov;42(11):2160–2165.
   PubMed Web of Science ®Google Scholar
• Dallocchio A, Canioni D, Ruemmele F, et al. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford). 2010 Sep;49(9):1694–1698.
   PubMed Web of Science ®Google Scholar